CNAT Conatus Pharmaceuticals Inc.

5.15
+0.05  (1%)
Previous Close 5.10
Open 5.14
Price To book 4.52
Market Cap 154525343
Shares 30,004,921
Volume 552,403
Short Ratio 7.77
Av. Daily Volume 272,836

SEC filingsSee all SEC filings

  1. 8-K - Current report 171066410
  2. S-3 - Registration statement under Securities Act of 1933 171038815
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171008678
  4. 8-K - Current report 17999914
  5. 8-K - Current report 17952121

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment commenced - March 15, 2017.
JZP-258
Cataplexy and Excessive Daytime Sleepiness in Narcolepsy
Phase 2b data due 2019.
Emricasan
NASH cirrhosis - ENCORE-LF trial
Phase 2b initiated November 2016. Data due 2018.
Emricasan
NASH cirrhosis - ENCORE-PH trial
Phase 2 topline data released Jan 2015
Emricasan
Acute-on-Chronic Liver Failure (ACLF)
Phase 2 data released September 2015.
Emricasan
Portal Hypertension
Phase 2b initiated May 2014. Topline data due 1H 2018.
Emricasan
Liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT)
Phase 2 completion of enrollment noted August 14, 2017. Data are due 1H 2019.
Emricasan
NASH fibrosis - ENCORE-NF trial
Phase 2 topline data released early January 2016
Emricasan
Liver Cirrhosis

Latest News

  1. EMA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC
  2. Will Conatus Liver Disease Candidate Drive Long-Term Growth?
  3. Hedge fund manager shuts firm to explore run for Connecticut governor
  4. Conatus (CNAT) Up 7% Since Earnings Report: Can It Continue?
  5. Conatus Pharmaceuticals Appoints Keith W. Marshall as Executive Vice President, Chief Operating Officer and Chief Financial Officer
  6. Will Conatus Key Candidate Emricasan Drive Long-Term Growth?
  7. Conatus Announces Completion of Enrollment in ENCORE-NF Phase 2b Clinical Trial of Emricasan in Patients with NASH Fibrosis
  8. Conatus (CNAT) Q2 Loss Narrows Y/Y, Revenues Beat Estimates
  9. Conatus reports 2Q loss
  10. Conatus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Program Updates
  11. Investor Network: Conatus Pharmaceuticals Inc. to Host Earnings Call
  12. Conatus Pharmaceuticals to Report Second Quarter 2017 Financial Results
  13. What's in Store for Conatus (CNAT) this Earnings Season?
  14. Why Conatus Pharma Wins With Newest Licensing Agreement
  15. H.C. Wainwright Bullish on Conatus Pharmaceuticals Inc (CNAT) on Back of Orphan Drug Designation for IDN-7314
  16. Company News for June 27, 2017
  17. Conatus's PSC Candidate Gets Orphan Designation in the U.S.
  18. Today's Research Reports on Stocks to Watch: Moleculin Biotech and Conatus Pharmaceuticals

SEC Filings

  1. 8-K - Current report 171066410
  2. S-3 - Registration statement under Securities Act of 1933 171038815
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171008678
  4. 8-K - Current report 17999914
  5. 8-K - Current report 17952121
  6. 8-K - Current report 17929949
  7. 424B5 - Prospectus [Rule 424(b)(5)] 17835501
  8. 8-K - Current report 17835336
  9. 424B5 - Prospectus [Rule 424(b)(5)] 17831648
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 17815606